Arialys RX is a company that specializes in providing data-driven solutions to optimize pharmaceutical sales and marketing strategies. They leverage analytics and technology to help clients in the pharmaceutical industry enhance their performance and achieve better outcomes.

Mitsuyuki Matsumoto

Arialys RX

Leveraging its networks in academia, biotech, venture capital and the pharmaceutical industry, Catalys Pacific has assembled a group of Strategic and Preferred Partners with whom to create asset-centric global bioventure companies.
Catalys Pacific begins operations as one of Japanʼs largest life sciences-focused investment firms. The firmʼs mission is to provide solutions to unmet medical needs for patients worldwide by creating and investing in companies that drive innovation in life sciences. Catalys Pacific maintains a strictly independent governance structure that ensures autonomous assessment and decision-making of its investments.

Mineralys Therapeutics

HilleVax

Phathom Pharmaceuticals

Catalys Pacific

Phathom Pharmaceuticals, a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced VOQUEZNA® (#vonoprazan) tablets for Erosive GERD and associated heartburn added to Express Scripts' national formularies.

#Phathom #GERD 

Read the release to learn more: 
https://lnkd.in/gq8QaDgw

Transposon Therapeutics, a biotechnology company developing a platform of novel, orally administered therapies for the treatment of neurodegenerative and aging-related diseases, announced final results from a Phase 2 study of TPN-101 for the treatment of Progressive Supranuclear Palsy and interim results from a Phase 2 study of TPN-101 for the treatment of C9orf72-related Amyotrophic Lateral Sclerosis and/or Frontotemporal Dementia.

#Transposon #PSP #ALS #FTD 

Read the release to learn more: 
https://lnkd.in/gtFgTrTw

Mineralys Therapeutics, a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease and other diseases driven by abnormally elevated aldosterone, announced $120 Million Private Placement Financing.

#Mineralys #PIPE 

Read the release to learn more: 
https://lnkd.in/g9DDsZiF

Today Renalys Pharma, Inc. was launched for developing medicines and treatments for Asian patients with renal disease.

Renalys Pharma’s efforts are centered on bringing #sparsentan, an investigational dual-acting treatment developed by #Travere Therapeutics, to IgA nephropathy patients in Japan and selected Asian countries. 

#IgAN

Read the release to learn more: 
https://lnkd.in/gPXz-e7V


We are pleased to announce that Mr. Ryutaro Shimazaki, a former Executive Officer at Kyowa Kirin Co., Ltd., has joined the team as a Partner.

He will contribute to our #inbound strategy to create new #biotech companies in Japan and to eliminate the drug lag between Japan and other countries through new #drug development.

See our release for more information:
https://lnkd.in/gifZ66Kf

Metric
Company Name	Arialys RX
Symbol
MSH ID	COM:ARIALYSRX
Market	PRIVATE
Sector	Healthcare & Health Services
Industry	Pharmaceutical Sales and Marketing Analytics
Country	JP
Stage
Employee Count	8
Website	arialysrx.com
LinkedIn	catalys-pacific
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

COM:ARIALYSRX

Arialys RX

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue